MedTrace Logo

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

NCT04401982 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-02

No results posted yet for this study

Summary

The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI).

The main questions this study aims to answer are:

* Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone?
* Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications?

Participants will:

* Be randomized to receive either latanoprost or Rocklatan
* Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and
* Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements.

Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.

Conditions

Interventions

DRUG

Rocklatan (Netarsudil 0.02%/ latanoprost 0.005)

Rocklatan (Netarsudil 0.02%/ latanoprost 0.005) one drop nightly for 14-28 days, if randomized to Rocklatan after 28-35 days on Latanoprost.

DRUG

Latanoprost (0.005%)

Latanoprost 0.005% one drop nightly for 28-35 days, then 14-28 days if randomized to continue on latanoprost.

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Osamah Saeedi, MD · University of Maryland, Baltimore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-02
Primary Completion
2027-03-17
Completion
2027-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04401982 on ClinicalTrials.gov